Skip to main content
Ovation Science Inc. logo

Ovation Science Inc. — Investor Relations & Filings

Ticker · OVAT ISIN · CA69016D1087 LEI · 549300A1P7L8HTTQXY56 CSE Professional, scientific and technical activities
Open in API
Filings indexed 252 across all filing types
Latest filing 2022-09-14 Regulatory Filings
Country CA Canada
Listing CSE OVAT

About Ovation Science Inc.

https://ovationscience.com/

Ovation Science Inc. is a research and development company specializing in advanced topical and transdermal product formulations. The core technology is Invisicare®, a patented, high-performance drug delivery system engineered to enhance the penetration and efficacy of active ingredients, particularly cannabis and hemp-derived cannabinoids (CBD, THC, CBN, CBG). Ovation utilizes pharmaceutical protocols to develop these formulations. Its primary business model involves licensing the Invisicare® technology and proprietary formulations to international partners for manufacturing and market distribution. The company also distributes finished topical CBD products under proprietary brands, such as the Invibe® MD wellness line and ARLO CBD Beauty anti-aging line, all leveraging the unique delivery capabilities of Invisicare®.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the granting of a new US patent to Ovation Science Inc. It discusses the patent details, the company's products, and forward-looking statements. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is primarily a corporate announcement about intellectual property and business progress, not a financial report, management change, or regulatory filing. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a corporate announcement that does not fit other specific categories.
2022-09-14 English
News release - English.pdf
Regulatory Filings
2022-09-07 English
Interim MD&A - English.pdf
Regulatory Filings
2022-08-29 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the Chief Financial Officer regarding the interim financial report and interim MD&A for the period ended June 30, 2022. It is a Form 52-109FV2 Certification of interim filings for a venture issuer. The content is primarily an officer certification attesting to the accuracy and fair presentation of the interim filings, without containing actual financial data or the interim report itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3008 characters) and it does not contain substantive financial statements or analysis, only the certification statement.
2022-08-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CEO of Ovation Science Inc. regarding the interim financial report and interim MD&A for the period ended June 30, 2022. It is a Form 52-109FV2, a Venture Issuer Basic Certificate, which certifies the accuracy and fair presentation of the interim filings. The document does not contain the actual interim financial statements or substantive financial data but is an officer certification related to the interim report. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than the interim report itself (IR). The document length is 3012 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2022-08-26 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for the three and six months ended June 30, 2022 and 2021. It contains detailed unaudited financial statements including statements of financial position, loss and comprehensive loss, changes in shareholders' equity, cash flows, and notes to the financial statements. The document explicitly states it is prepared in accordance with IFRS and IAS 34, which governs interim financial reporting. The presence of actual financial data and comprehensive financial analysis for a period shorter than a full fiscal year confirms this is an interim or quarterly report. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2022
2022-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.